PreciPoint GmbH
- Industry
- Medical Equipment Manufacturing
- Founded Year
- 2018
- Headquarters
- Freising, Germany
- Employee Count
- 50
Key People
- Dr. Markus D. Eckstein - CEO
- Dr. Michael Grf - CTO
- Dr. Thomas Schmid - COO
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with over a decade in their respective fields.
The leadership team's significant experience in their respective domains suggests a strong foundation for the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Strong
Summary: Digital pathology addresses critical needs in modern diagnostics, enhancing efficiency and accuracy.
The increasing prevalence of chronic diseases and the need for precise diagnostics underscore the importance of digital pathology solutions in modern healthcare.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The digital pathology market is highly competitive with numerous established players.
The presence of major players like Leica Biosystems, Philips, and Roche Diagnostics indicates a highly competitive landscape, posing challenges for newer entrants.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing digital pathology solutions involves moderate technical challenges.
The integration of hardware and software in digital pathology systems presents moderate technical challenges, necessitating expertise in both domains.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents to protect its innovations.
Applying for patents suggests the company is actively developing proprietary technologies, which can provide a competitive edge in the market.
- Financing
-
Aspect: Medium
Summary: The company has secured moderate funding from investors.
The current funding supports initial operations, but further investment may be required to expand market reach and product development.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company is pursuing necessary regulatory approvals for its products.
Obtaining 510(k) or PMA approvals is critical for commercializing medical devices in key markets, requiring thorough compliance with regulatory standards.
Opportunity Rollup
- Odds of Success
- 3.4
- Peak Market Share
- 4.6
- Segment CAGR
- 7.7%
- Market Segment
- Digital Pathology
- Market Sub Segment
- Digital Pathology Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.23 |
| 2 | 0.69 |
| 3 | 1.61 |
| 4 | 3.22 |
| 5 | 4.60 |
Key Takeaway
PreciPoint GmbH operates in a growing digital pathology market but faces significant competition and technical challenges.